Creating immune organoids to study pediatric cancers
Official title: Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)
Run by Gustave Roussy, Cancer Campus, Grand Paris · NCT05890781 · Data updated 2026-11-12
This study is trying to create mini immune systems from kids' tissues to see how they respond to different types of pediatric cancers.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | Any age to 25 Years |
| Sex | All |
| Enrollment | 108 (estimated) |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris Academic / other |
| Locations | 2 sites (Villejuif and 1 other locations) |
| Status | Recruiting |
| Started | May 12, 2023 |
| Main results expected | May 2028 |
| Study ends | May 2028 |
| Registry record updated | February 9, 2026 |
| Trial ID | NCT05890781 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are pediatric patients aged 25 years or younger with a medical suspicion or diagnosis of brain tumors, renal tumors, neuroblastoma, or sarcomas.
✕Probably not a fit
Patients with histologies not specified in the inclusion criteria or those unable to provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to engineer immune organoids from tissues of pediatric patients using induced-pluripotent stem cells (iPSC). By utilizing skin biopsies, fresh tumor samples, blood samples, healthy tissue, and cerebrospinal fluid, the research seeks to better understand the immune response in various pediatric cancers, including brain tumors, kidney tumors, neuroblastoma, and sarcomas. The approach focuses on leveraging patient-derived materials to create organoids that can mimic the tumor environment and immune interactions. This innovative methodology may provide insights into treatment responses and disease mechanisms.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment strategies for pediatric cancers.
How similar studies have gone: While the approach of engineering immune organoids is innovative, similar studies have shown promise in understanding cancer biology and treatment responses, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied * Medical suspicion or diagnosis of one of the following diseases, regardless of stage: * Brain tumors * Renal tumors * Neuroblastoma * Sarcomas * Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol. * Affiliated to a social security system or beneficiary of the same. Exclusion Criteria: * Any histology not mentioned in the inclusion criteria * Adult patient or parents/guardians incapable/incapable of giving its/their consent * Patients deprived of their liberty by a judicial or administrative decision
Where it's running
-
Gustave Roussy
Villejuif, France Recruiting -
Hopital Necker
Paris, Île-de-France Region, France Recruiting
Study contacts
- Study coordinator: Claudia PASQUALINI, MD
- Email: claudia.pasqualini@gustaveroussy.fr
- Phone: +33 (0)1 42 11 55 31
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding recovery in children after cancer surgery
This study looks at how children aged 3-18 and their families recover after cancer surgery by using smartwatches and surveys to gather information over a year.
-
Using modified T cells to treat certain solid tumors in children and young adults
This study is testing a new treatment using modified T cells to see if it can help children and young adults with tough-to-treat solid tumors.
-
Using cabozantinib to prevent recurrence in high-risk pediatric solid tumors
This study is testing if the drug cabozantinib can help prevent high-risk pediatric solid tumors, like neuroblastoma and sarcoma, from coming back after treatment.
-
Optimizing PET Imaging with 18F-DOPA for Various Conditions
This study is testing if a special imaging technique using 18F-DOPA can help doctors see and understand conditions like congenital hyperinsulinism, neuroblastoma, neuroendocrine tumors, Parkinson's disease, and Lewy body dementia better in both kids and adults.
-
Collecting and storing samples from children and adults with common childhood cancers
This study is collecting and storing samples from children and adults with common childhood cancers to help researchers learn more about these diseases and find better treatments.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.